We have located links that may give you full text access.
Exercise-induced hematuria exacerbated by improper hydration, low RBC MCV and dapagliflozin use.
Biomedicine & Pharmacotherapy 2023 September 21
BACKGROUND: Dapagliflozin is a reversible, highly potent, and selective Sodium-Glucose Co-Transporter-2 inhibitor indicated for the treatment of type 2 diabetes. It is generally well tolerated, with a low risk of hypoglycaemia and diabetic ketoacidosis.
CASE PRESENTATION: We report a new adverse effect of dapagliflozin in a form of a transient hematuria, presenting in a 54-years-old male patient with type 2 diabetes after exercise and insufficient hydration. The process of hematuria in the patient is strongly linked with initial period of treatment.
CONCLUSION: Dapagliflozin appears to have a rare adverse effect in the form of transient hematuria. Exercise, insufficient hydration, and low RBC MCV may play a role in such episodes.
CASE PRESENTATION: We report a new adverse effect of dapagliflozin in a form of a transient hematuria, presenting in a 54-years-old male patient with type 2 diabetes after exercise and insufficient hydration. The process of hematuria in the patient is strongly linked with initial period of treatment.
CONCLUSION: Dapagliflozin appears to have a rare adverse effect in the form of transient hematuria. Exercise, insufficient hydration, and low RBC MCV may play a role in such episodes.
Full text links
Related Resources
Trending Papers
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app